CEO Doug Drysdale joins Michael D. Levitt on the Breakfast Leadership Network to talk about the paradigm shift #Cybin is leading in depression treatment, the potential impact on the mental health system, and our long-term vision. Watch: youtube.com/watch?v=RlhLy1… #Neuropsychiatry

The American Psychological Association has recognized psychologists pursuing prudent pathways for #psychedelics as a top 10 trend in the field of psychology in 2025. Cybin is proud to be a leader in groundbreaking studies shedding light on how psychedelics alter the brain to facilitate lasting improvements

We are #hiring! SENIOR MEDICAL WRITER United States, Remote, Full-time linkedin.com/jobs/view/4131… Do you know a potential future Cybinaut? Send them the link to apply! #Cybin #DrugDevelopment #Biotech #ClinicalScientist #Neuroscienc

Cybin’s milestones for the first-half of 2025 include a topline efficacy data readout from our CYB004 Phase 2 GAD study and the initiation of the EXTEND and EMBRACE pivotal studies of CYB003. Learn more: lnkd.in/gnHd43k2 #Neuropsychiatry #MentalHealthInnovation

With a combined 60 Investigational New Drug applications, 37 exits, and 300 peer-reviewed publications by scientific leadership, our team is realizing a mental health revolution. Learn more: cybin.com/our-team/ #Neuropsychiatry #MentalHealthInnovation #BreakthroughTherapy

Psychedelics will make you rethink your whole life And maybe in a modern age what we’ve been missing is in fact ancestral [plant] wisdom Doug Drysdale joins us to talk about his life, work and CybinInc’s mission to revolutionize mental healthcare with psychedelics Link below!

We are #hiring! ASSOCIATE DIRECTOR, CLINICAL DEVELOPMENT – ADDITIONAL HIRE United States, Remote, Full-time linkedin.com/jobs/view/4136… Do you know a potential future Cybinaut? Send them the link to apply!

CEO Doug Drysdale spoke about #Cybin's recent breakthroughs and milestones at the Future of Psychedelics panel at the Sachs Associates' 8th Annual Neuroscience Innovation Forum earlier this month in #SanFrancisco. #NeuroPsychiatry #MentalHealth #Psychedelics

Nearly 70% of #MDD patients take antidepressants. #Cybin is developing #CYB003 as an acute, adjunctive therapy—potentially enabling immediate treatment without patients waiting to withdraw and eliminating logistical hurdles. Learn more: loom.ly/SRZ80Bk

CYB004 is #Cybin’s proprietary, deuterated DMT molecule in a Phase 2 study for Generalized Anxiety Disorder (#GAD) — potentially offering a short-duration treatment to disrupt negative thought patterns and transform the care of people with GAD. Learn more:

There are just 4 US-approved medicines for Generalized Anxiety Disorder — all SSRIs & SNRIs. With no new approval in 15+ years, they provide only limited relief to many sufferers. In recent market research commissioned by Cybin, we learned from psychiatrists that the majority of

#GAD is characterized by persistent and excessive worry about health, work, social interactions, and everyday routines. Symptoms include restlessness, fatigue, difficulty concentrating, irritability, muscle tension, and sleep disturbances. Learn more: loom.ly/WEGP3es

Rapid and durable effects have been observed in #DMT studies, with: ✓ Improvements in anxiety and well-being scores ✓ Safe and well-tolerated intramuscular route ✓ Safe and well-tolerated when co-administered with SSRIs Learn more: loom.ly/WEGP3es

"What we’re seeing with our treatment is, after just two doses, and I don’t mean two doses a week or two doses a month, I mean just two doses, we see 75% of patients in remission from their depression and 71% still in remission one year later." Read #Cybin CEO Doug Drysdale's

“Preparation for the commercialization of our clinical stage programs is a top priority, and aligning ourselves with Osmind will help us accelerate our goals,” said #Cybin CEO Doug Drysdale. "Osmind’s extensive network of over 800 psychiatry clinics in the U.S., combined

“This strategic partnership agreement model serves to take advantage of the deep expertise of each individual site and ensure that protocols and best practices are shared consistently,” said #Cybin CEO Doug Drysdale Learn more: ir.cybin.com/investors/news/

“It’s truly an honor to return to the Milken Institute Conference and to contribute to the discourse around the opportunities we have as drug developers today,” said #Cybin CEO Doug Drysdale  Learn more: loom.ly/4r6Nng0 #MIGlobal

May is #MentalHealthAwarenessMonth, and at #Cybin, we're pioneering new paths in mental healthcare for the benefit of patients worldwide. Too many are suffering in silence. This month, we rededicate ourselves to raising awareness and realizing new treatment options. Together, we

CybinInc was honored to participate in the 28th Annual Milken Institute Global Conference on May 5th, 2025, where CEO Doug Drysdale discussed the role of innovation in realizing new standards of care for the treatment of mental health as part of a panel discussion on the Global

#ICYMI: Last week, Cybin CEO Doug Drysdale was featured in a fireside chat hosted by Jim Molloy at Alliance Global Partners (A.G.P.)'s Virtual Healthcare Showcase. Tune in to the replay to learn more about Cybin's progress with its lead clinical-stage programs CYB003 and CYB004,